SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...

The upgrade follows positive readouts from one of Roche’s fenebrutinib Phase 3 trials in relapsing multiple sclerosis, known ...

Evolus dermal filler, Evolysse™ Lift, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity ...

Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting ...

The Medtronic investment and the underwritten public offering of common stock position Anteris to continue to execute the global PARADIGM Trial and to continue investing in research that can transform ...

Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting (CINV)Phase 3 study met all primary and secondary endpoints, demonstrating superior ...

Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to ...

Amid political uncertainty, South Africa grapples with the legacy of Commissions of Inquiry, which, while intended as ...

Multiple cohorts now report excellent mid- and long-term survivorship for cementless total knee arthroplasty systems using 3D ...

On January 20, the Russian military launched a massive combined arms strike on the Neo-Nazi junta, hitting hundreds of ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

ZGF Architects’ Solvei Neiger discusses what she sees as the biggest opportunity for change in healthcare design in 2026.